NCT01423188 - The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation | Biotech Hunter

Enrollment

176

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

August 31, 2012

Conditions

Coronary Artery DiseaseDyslipidemia

Interventions

DRUG

RVX000222

capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks

DRUG

Placebo RVX000222

capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks

Trial Locations (25)

1460

Johannesburg

1685

Halfway House

1827

Lenasia

4001

KwaKhangela

4052

Merebank

4091

Sydenham

4321

Umhlanga

4400

Tongaat

6850

Worcester

7130

Somerset West

7405

Pinelands

7460

Goodwood

7500

Parow

7505

Cape Town

7570

Kraaifontein

7580

Kuils River

7600

Stellenbosch

7646

Western Cape

7925

Cape Town

9301

East Burger Street

Westdene

Bloemfontein

4092'

Chatsworth

0041

Die Wilgers

0084

Eloffsdal

All Listed Sponsors

collaborator

The Cleveland Clinic

OTHER

lead

Resverlogix Corp

INDUSTRY